Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

The Efficacy of a Remote Cognitive Remediation Therapy (CRT) Program on Parkinson's Disease

3. oktober 2022 oppdatert av: New York Institute of Technology

Purpose/Goal: To determine if a remote computerized cognitive remediation program (CRT) can stabilize or improve cognitive functioning in a group of patients from the New York Institute of Technology Academic Health Care Center with Parkinson's disease (PD) after three months of intervention.

Hypothesis: Patients with PD who present with current cognitive deficits will show improvement in such deficits after three months of participation in a remotely supervised structured Cognitive Remediation Therapy Program (CRT) compared to control subjects with PD who receive treatment as usual.

Research design: Pilot study. Prospective randomized treatment and control comparison pre-post study.

Studieoversikt

Status

Fullført

Studietype

Intervensjonell

Registrering (Faktiske)

25

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • New York
      • Old Westbury, New York, Forente stater, 11568
        • New York Institute of Technology

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

40 år til 85 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Subjects must be currently enrolled in the Rock Steady Boxing Program at the Adele Smithers Parkinson's Disease Center.
  2. Subjects must be between 40 and 85 years old (including both ages) at the time of study screening.
  3. Subjects must have a diagnosis of Parkinson's disease by a physician.
  4. Subjects must have a MOCA score of 20 or above.
  5. Subjects must demonstrate adequate decisional capacity, in the judgment of the consenting study staff member, to make a choice about participating in this research study.
  6. Subjects must have been clinically stable for 2 weeks prior to consent; in the judgment of the Investigator.
  7. Subjects must have the visual, auditory, and motor capacity to use the intervention in the judgment of the Principal Investigator.
  8. Subjects must be technologically capable of utilizing a computer and navigating through the programs.
  9. Subjects must be mechanically capable of utilizing a computer and computer mouse.

Exclusion Criteria:

  1. Subjects should not be participating in a concurrent research study or other interventional clinical trial 30 days prior to consenting.
  2. Subjects should not have a history of mental retardation or pervasive developmental disorder; or other co-morbid neurological disorder (e.g., epilepsy.)
  3. Subject is unable to physically use a computer or a computer mouse.
  4. Subject is unable to or refuses to give consent.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Støttende omsorg
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Parkinson's Disease Patients receiving Cognitive Remediation Therapy
Parkinson's Disease Subjects will undergo 10 weeks of Brain HQ training, 2 times a week an hour at a time. Also patients pre- and post-intervention RBANS and PDQ-39 scores.
Brain HQ games involving training cognitive abilities like memory and attention, made up of adapting tasks or creating our own.
Ingen inngripen: Parkinson's Disease Patients not receiving Cognitive Remediation Therapy
Parkinson's Disease Subjects will receive no intervention, but still undergo pre- and post-intervention RBANS and PDQ-39 scores.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Pre-Intervention
Tidsramme: Initially, before any intervention/start of study.
A brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory.
Initially, before any intervention/start of study.
The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) Post-Intervention
Tidsramme: 10 weeks after intervention/completion of the study.
A brief, individually administered test measuring attention, language, visuospatial/constructional abilities, and immediate and delayed memory.
10 weeks after intervention/completion of the study.
Parkinson's Disease Questionnaire (PDQ-39) Pre-Intervention
Tidsramme: Initially, before any intervention/start of study.
A test that assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.
Initially, before any intervention/start of study.
Parkinson's Disease Questionnaire (PDQ-39) Post-Intervention
Tidsramme: 10 weeks after intervention/completion of the study.
A test that assesses how often people affected by Parkinson's experience difficulties across 8 dimensions of daily living including relationships, social situations and communication.
10 weeks after intervention/completion of the study.
Montreal Cognitive Assessment (MOCA) Pre-Intervention Screening
Tidsramme: Initially, before any intervention/start of study.
A rapid screening instrument for mild cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation.
Initially, before any intervention/start of study.

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. juni 2021

Primær fullføring (Faktiske)

1. april 2022

Studiet fullført (Faktiske)

1. april 2022

Datoer for studieregistrering

Først innsendt

17. juni 2021

Først innsendt som oppfylte QC-kriteriene

28. juni 2021

Først lagt ut (Faktiske)

8. juli 2021

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. oktober 2022

Siste oppdatering sendt inn som oppfylte QC-kriteriene

3. oktober 2022

Sist bekreftet

1. oktober 2022

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere